Lederle's Damox
Executive Summary
FDA's "Approved Rx Drug Products List with Therapeutic Equivalence Evaluations" supplement for Aug. 1984-Nov. 1984 incorrectly lists the patent expiration date for Diamox ("The Pink Sheet" Dec. 24, p. 10). The patent cited, #3584005 (not #3544005 as listed), is a process patent and therefore not valid for inclusion in FDA's listing. The list includes only chemical entity or use patents. Diamox will be deleted from future supplements
You may also be interested in...
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacid Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.